GS-7977/GS-5885: Phase I started

Gilead announced in its 2Q12 earnings conference call that it began a Phase I bioavailability trial to evaluate GS-7977/GS-5885 in patients with HCV genotype 1 infection. The company said if the Phase I data show adequate exposure of the compounds, it plans to begin a Phase III trial next quarter in treatment-naive patients with HCV genotype 1 infection. Details were not disclosed. ...